JUBILANT GENERICS LIMITED v. DECHRA VETERINARY PRODUCTS LLC

District Court, D. Maine·Decided March 28, 2024·No. 2:23-cv-00237·Unknown

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MAINE

JUBILANT GENERICS LIMITED, ) ) Plaintiff, ) ) v. ) 2:23-cv-00237-JDL ) DECHRA VETERINARY ) PRODUCTS, LLC, ) ) Defendant. )

ORDER ON PLAINTIFF’S MOTION TO DISMISS DEFENDANT’S COUNTERCLAIM AND COMPEL ARBITRATION

Plaintiff Jubilant Generics Limited (“Jubilant”) filed a Complaint on June 7, 2023 (ECF No. 1), against its former business partner, Defendant Dechra Veterinary Products, LLC (“Dechra”). Dechra filed an Answer and Counterclaim, on August 4, 2023 (ECF No. 30). Jubilant subsequently filed a Motion to Dismiss Defendant’s Counterclaim and Compel Arbitration (ECF No. 34; “the Motion”). In the Motion, Jubilant argues that the parties previously entered into a binding agreement requiring Dechra’s counterclaims to be arbitrated. Jubilant contends that its own claims are properly decided by the Court because they are exempted from the parties’ arbitration agreement, so the Motion seeks to compel arbitration of Dechra’s counterclaims only. For the reasons that follow, I grant Jubilant’s request to compel arbitration, but I deny the Motion in part because I conclude that the counterclaims should be stayed pending arbitration rather than dismissed at this time. I. BACKGROUND

Plaintiff Jubilant is a pharmaceutical company based in India that specializes in the development, manufacturing, and supply of generic drugs. Defendant Dechra is a veterinary pharmaceutical company based in the United States that develops, manufactures, and distributes animal health products. Jubilant and Dechra were business partners for a number of years. To facilitate their business partnership, the parties1 entered into two agreements that are relevant to this case: a Confidentiality Agreement executed on

January 18, 2007 (the “Confidentiality Agreement”), and a Licensing and Supply Agreement executed on December 10, 2007 (the “Agreement”).2 Under the Agreement, Jubilant agreed to manufacture an antibiotic tablet used to treat animals (“the product”), and Dechra agreed to obtain regulatory approval and sell the product in the United States. The Agreement contains an arbitration provision. Section 14 of the Agreement, titled “Arbitration” (the “arbitration provision”), provides in part that,

“[e]xcept for any violation of any obligation under Section 10, all Disputes relating in any way to this Agreement shall be resolved exclusively through arbitration conducted in accordance with the arbitration rules of the International Chamber of

1 Technically, Jubilant and Dechra are successors to the entities that executed the Confidentiality Agreement and the Licensing and Supply Agreement. 2 Jubilant asserts that the Agreement was amended on March 28, 2018. The parties have attached to their pleadings slightly different versions of the Agreement. Compare ECF No. 1-1, with ECF No. 30-1. Those differences are not consequential here. Commerce as then in effect.”3 ECF No. 1-1 at 20; ECF No. 30-1 at 38. Section 10, in turn, is titled “Confidentiality” and governs the use, disclosure, and return of “Confidential Information,” ECF No. 1-1 at 14-16; ECF No. 30-1 at 26-28, defined

elsewhere in the Agreement as “all scientific, manufacturing, technical, clinical, regulatory, financial, pricing, commercial, sales, marketing, customer and other information and data related to any of the Product, the [active pharmaceutical ingredient], or to the objects of this Agreement, whether disclosed orally or in Documents,” ECF No. 1-1 at 3; ECF No. 30-1 at 3. The Confidentiality Agreement does not mention arbitration.

The parties’ business arrangement eventually broke down, after which Jubilant initiated this civil action against Dechra. Jubilant asserts the following claims in its Complaint: (1) breach of contract (Count I); (2) misappropriation of trade secrets in violation of the Maine Uniform Trade Secrets Act, 10 M.R.S.A. §§ 1541- 1548 (West 2024) (Count II); (3) violation of the federal Defend Trade Secrets Act, 18 U.S.C.A. § 1836 (West 2024) (Count III); and (4) an action for replevin relating to Jubilant’s confidential information (Count IV). Count I alleges that Dechra breached

the Agreement and the Confidentiality Agreement by impermissibly retaining, using, and disclosing Jubilant’s Confidential Information. Counts II and III allege that Jubilant’s Confidential Information is a trade secret, and Dechra’s continued use of and failure to return the Confidential Information violates state and federal trade secrets laws. Count IV requests a court order requiring Dechra to return and stop

3 Because the parties have provided slightly different versions of the Agreement, supra note 2, I have cited to the relevant language in both attachments where appropriate. interfering with Jubilant’s Confidential Information, and to compensate Jubilant for damages. Dechra, in response, asserts the following counterclaims against Jubilant:

(1) breach of contract (Count I); (2) an alternative breach of contract claim (Count II); (3) a request for declaratory judgment (Count III); and (4) a request for attorney’s fees (Count IV). Count I alleges that Jubilant willfully and materially breached the Agreement by failing to supply the product, not following good manufacturing practices, providing adulterated drugs, failing to support a required technology transfer, and failing to indemnify Dechra for costs arising from the breach. In the

alternative, Count II alleges that Jubilant breached the Agreement by failing to supply the product, refusing to pay the cost of a replacement drug, and failing to reimburse Dechra for costs related to the technology transfer. Count III requests a declaration that Dechra owns the regulatory approval for the product and all rights flowing from that approval including, but not limited to, commercializing the approval, selling the product in the United States, and selling the approval to a different pharmaceutical company for potential commercialization. Count IV

requests attorney’s fees. II. DISCUSSION A. Legal Standard: Motion to Compel Arbitration Jubilant seeks to compel arbitration of Dechra’s counterclaims under the

Federal Arbitration Act (“FAA”), 9 U.S.C.A. §§ 1-16 (West 2024). The FAA provides in part: A party aggrieved by the alleged failure, neglect, or refusal of another to arbitrate under a written agreement for arbitration may petition any United States district court which, save for such agreement, would have jurisdiction under title 28, in a civil action or in admiralty of the subject matter of a suit arising out of the controversy between the parties, for an order directing that such arbitration proceed in the manner provided for in such agreement. Id. § 4. “In deciding a motion to compel arbitration, a court must ascertain whether: ‘(i) there exists a written agreement to arbitrate, (ii) the dispute falls within the scope of that arbitration agreement, and (iii) the party seeking an arbitral forum has not waived its right to arbitration.’” Gove v. Career Sys. Dev. Corp., 689 F.3d 1, 4 (1st Cir. 2012) (quoting Combined Energies v. CCI, Inc., 514 F.3d 168, 171 (1st Cir. 2008)). Jubilant argues, and Dechra acknowledged at oral argument, that the parties have a valid written agreement to arbitrate certain disputes and that Dechra’s counterclaims fall within the scope of that agreement. The parties disagree, however, about whether Jubilant has waived its right to compel arbitration of Dechra’s counterclaims. Thus, the key questions here center on waiver and who—the Court or the arbitrator—should decide the arbitration-related disagreements that the Motion presents. B. Waiver 1.

Free access — add to your briefcase to read the full text and ask questions with AI

JUBILANT GENERICS LIMITED v. DECHRA VETERINARY PRODUCTS LLC, (D. Me. 2024).

JUBILANT GENERICS LIMITED v. DECHRA VETERINARY PRODUCTS LLC (JUBILANT GENERICS LIMITED v. DECHRA VETERINARY PRODUCTS LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Dean Witter Reynolds Inc. v. Byrd
470 U.S. 213 (Supreme Court, 1985)
First Options of Chicago, Inc. v. Kaplan
514 U.S. 938 (Supreme Court, 1995)
Marie v. Allied Home Mortgage Corp.
402 F.3d 1 (First Circuit, 2005)
Combined Energies v. CCI, INC.
514 F.3d 168 (First Circuit, 2008)
Awuah v. Coverall North America, Inc.
554 F.3d 7 (First Circuit, 2009)
Apollo Computer, Inc. v. Helge Berg
886 F.2d 469 (First Circuit, 1989)
Kpmg LLP v. Cocchi
132 S. Ct. 23 (Supreme Court, 2011)
Jason Bercovitch v. Baldwin School, Inc.
133 F.3d 141 (First Circuit, 1998)
Gove v. Career Systems Development Corp.
689 F.3d 1 (First Circuit, 2012)
Oracle America, Inc. v. Myriad Group A.G.
724 F.3d 1069 (Ninth Circuit, 2013)
BG Group, PLC v. Republic of Argentina
134 S. Ct. 1198 (Supreme Court, 2014)
Joca-Roca Real Estate LLC v. Brennan, Jr.
772 F.3d 945 (First Circuit, 2014)
FPE Foundation v. Cohen
801 F.3d 25 (First Circuit, 2015)
Henry Schein, Inc. v. Archer & White Sales, Inc.
586 U.S. 63 (Supreme Court, 2019)
Patton v. Johnson
915 F.3d 827 (First Circuit, 2019)
Cutler Associates, Inc. v. Palace Construction, LLC
132 F. Supp. 3d 191 (D. Massachusetts, 2015)